SLC5A2 and infection: Within current clinical practice, concerns persist regarding the potential adverse events associated with SGLT-2 inhibitors, particularly UTIs13 and DKA,34 which may pose a greater risk for KTRs due to their concurrent administration of immunosuppressive agents.35 However, our meta-analysis observed that SGLT-2 inhibitors did not increase risk of serious infection, including UTIs, genital mycotic infection, and urosepsis, compared to the control group.